New Frontier Labs

New Frontier Labs is a drug discovery group focused on the development of a novel class of therapeutic agents known as Membrane Acting Immunomodulators (MAIMS). These drugs function by altering the fluidity of cellular plasma membranes to address various medical conditions. The company holds multiple United States patents for these indications, including treatments for insulin resistance, type 2 diabetes, dyslipidemia, musculoskeletal pain, inflammatory dermatoses, obesity, and complications from Brown Recluse spider bites.

The company operates as a research-driven entity that seeks to out-license its intellectual property for further development and commercialization. Recently, New Frontier Labs formed a collaborative alliance with Transcell Biologics and 20/15 Visioneers to utilize human-relevant models and AI-enabled technologies, such as Digital Animal Replacement Technology (DART), to advance their drug discovery programs. This partnership aims to bridge human therapeutic target insights with existing research data, focusing on evaluating the structure-activity relationships of their drug candidates to facilitate the development of novel, human-centric therapies.